Nama's AI scorecard currently rates Addus HomeCare Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ADUS's P/E ratio?

Addus HomeCare trades at a trailing price-to-earnings ratio of 17.9.

When does ADUS report earnings?

Addus HomeCare's next scheduled report is on Feb 22, 2027. Analysts expect EPS of $1.91.

What is the ADUS price target?

The median analyst price target from 13 analysts is $137.00, with a range of $101.00 – $155.00.

Is ADUS Shariah compliant?

Nama's AAOIFI-style screen reads Addus HomeCare as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Addus HomeCare (ADUS)

Healthcare · Medical Care Facilities · NASDAQ

Addus HomeCare (ADUS) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $2.32B, a trailing price-to-earnings ratio of 17.9 and a free-cash-flow yield of 4.5%. Over the most recent reported fiscal year, revenue grew 23.2% and free cash flow per share fell 7.8%. Nama's AI scorecard rates it Buy, 7.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -0.8% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-9.1%

How far the last close sits under the highest price of the past five years.

Market cap	$2.32B
Trailing P/E	17.9
Price / book	2.0
Price / sales	1.6
FCF yield	4.5%
Dividend yield	—
Gross margin	32.4%
Operating margin	10.0%
Net margin	7.1%
Revenue growth (YoY)	+23.2%
Revenue growth (3-yr annual)	+14.4%
EPS growth (YoY)	+19.1%
FCF/share growth (YoY)	-7.8%
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

ADUS earnings

Next report: Feb 22, 2027 (Q4 2026, EPS estimate $1.91). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$1.83	$1.79	+2.2%	$387.73M
Q2 2026	Aug 3, 2026	$1.73	$1.70	+1.8%	$377.42M
Q1 2026	May 4, 2026	$1.62	$1.54	+5.2%	$363.61M
Q4 2025	Feb 23, 2026	$1.77	$1.72	+2.9%	$373.08M

ADUS analyst price target

Median target $137.00 from 13 analysts, ranging $101.00 – $155.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live ADUS data on Nama Insights →

ADUS FAQ

Is ADUS a buy?: Nama's AI scorecard currently rates Addus HomeCare Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ADUS's P/E ratio?: Addus HomeCare trades at a trailing price-to-earnings ratio of 17.9.
When does ADUS report earnings?: Addus HomeCare's next scheduled report is on Feb 22, 2027. Analysts expect EPS of $1.91.
What is the ADUS price target?: The median analyst price target from 13 analysts is $137.00, with a range of $101.00 – $155.00.
Is ADUS Shariah compliant?: Nama's AAOIFI-style screen reads Addus HomeCare as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.